Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries (Sun Pharma) has reported results for the fourth quarter (Q4FY26) and year ended March 31, 2026.

The company has reported 70.19% fall in its net profit at Rs 608.70 crore for the quarter under review as compared to Rs 2,041.97 crore for the same quarter in the previous year. The total income of the company has decreased by 31.80% at Rs 4,986.81 crore for Q4FY26 as compared to Rs 7,311.58 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 26.24% rise in its net profit at Rs 2,714.03 crore for the fourth quarter ended March 31, 2026 as compared to Rs 2,149.88 crore for the same quarter in the previous year. The total income of the company has increased by 11.04% at Rs 15,070.29 crore for Q4FY26 as compared to Rs 13,571.71 crore for the corresponding quarter previous year.

For the year ended March 31, 2026, the company has reported 37.95% fall in its net profit at Rs 2,623.42 crore as compared to Rs 4,228.08 crore for the previous year. The total income of the company has decreased by 9.34% at Rs 21,173.97 crore for year under review as compared to Rs 23,356.54 crore for year ended March 31, 2025.

For the year ended March 31, 2026, on the consolidated basis, the company has reported 5.04% jump in its net profit at Rs 11,479.42 crore as compared to Rs 10,929.04 crore for the previous year. The total income of the company increased by 10.80% at Rs 60,433.76 crore for year under review as compared to Rs 54,543.48 crore for year ended March 31, 2025.